REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSttranslating…

Market impact notice: REGN shares allegedly lost $102.09 from the Class Period high after disclosures about a Phase III Fianlimab-Libtayo protocol change and failed primary endpoint challenged earlier positive trial-risk messaging. NEW YORK, Sept. 3, 2026 /PRNewswire/ --…

Sign in to join the discussion.

Loading comments…